ArticleDiscover oncology2025
TAM family kinases are potential candidate targets for therapeutic intervention in chronic myeloid leukemia.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- An AI-enabled structural atlas decodes kinase specificity across the human proteome.Nature biotechnology · 2026Article
- Drug resistance in chronic myeloid leukemia: the involvement of Galectin-1 and Galectin-3.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic Myeloid Leukemia (CML) is a hematologic disorder depicted by BCR::ABL1 translocation; a constitutively active tyrosine kinase (TK) and a hallmark of CML. Kinase domain mutations and the activation of alternative signaling pathways lead to drug resistance in CML. TAM family kinases, including TYRO3 receptor tyrosine kinase (TYRO3-RTK), AXL receptor tyrosine kinase (AXL-RTK), and MER receptor tyrosine kinase (MERTK), are often overexpressed in various types of cancers. AXL-RTK plays a significant role in the survival of leukemic stem cells (LSCs) and provides adaptive resistance to CML cells against Tyrosine kinase inhibitors (TKIs). However, the specific functions and mechanisms of two other receptors, TYRO3-RTK and MERTK, in both sensitive and resistant CML cells are not yet documented. Therefore, this study aimed to explore the expression patterns and roles of TAM family kinases in sensitive and resistant CML. METHODS AND
resultsWe have developed an Imatinib-Resistant CML model (K562-R) by administering an increasing dose of Imatinib over 4 months. Proliferation was evaluated through MTT assay. Apoptosis and expression analysis were conducted through the DNA fragmentation assay and RT-PCR, respectively. TYRO3-RTK, AXL-RTK, and MERTK were found to be 2, 7 and 25 folds higher in K562-R than K562-S cells respectively. Pharmacological targeting of TYRO3-RTK with LDC1267, AXL-RTK with R428, and MERTK with UNC2250 TAM inhibitors significantly interfered with the proliferation potential of both K562-S and K562-R cells. TAM kinase inhibitors also abridged colony formation in K562-S and K562-R cells. We have observed an additive antiproliferation effect by co-targeting TAM kinases with Imatinib in K562-S cells and a synergistic effect in K562-R cells. Mechanistically, apoptosis induction independent of p53, differential upregulation of cell cycle inhibitors, including p16, p21, and p27 in K562-S and K562-R cells were observed to be related with the proliferation inhibition. Furthermore, we showed that TAM family inhibitors interfere with the Wnt/β-catenin pathway by downregulation of downstream targets c-Myc, Axin2, its regulators, EYA3, and AXL-RTK in both K562-S and K562-R cells.
conclusionTAM family kinase inhibitors significantly reduce the proliferation and colony formation of K562-S and K562-R cells by inducing apoptosis, interfering with Wnt/β catenin pathway, and upregulating cell cycle inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.